Tegaserod.

Abstract

Tegaserod is a serotonin (5-hydroxytryptamine; 5-HT) receptor partial agonist which has been investigated for the treatment of irritable bowel syndrome (IBS). Specifically, it binds with high affinity to human 5-HT4 receptors, thereby stimulating the release of neurotransmitters and the peristaltic reflex in vitro. Small bowel transit (increased colonic filling over 6 hours) was accelerated in patients with constipation-predominant irritable bowel syndrome (IBS) receiving oral tegaserod 2mg twice daily for 1 week compared with those receiving placebo. In addition, there was a mean 20% increase of proximal colonic emptying in these patients. Oral tegaserod 2 (p < 0.05) or 6mg twice daily improved symptoms of abdominal discomfort, bloating and constipation (assessed using a Subjects' Global Assessment Scale) compared with placebo in patients with constipation-predominant IBS in a double-blind, dose-ranging study. The most frequent adverse events in patients with constipation-predominant IBS receiving oral tegaserod were transient diarrhoea and flatulence. No clinically relevant changes in blood pressure, pulse rate, QRS or QTc interval were reported with tegaserod doses of 25 to 100mg.

• Authors: L J Scott, C M Perry
• Journal: Drugs (Drugs) Vol. 58 Issue 3 Pg. 491-6; discussion 497-8 (Sep 1999) ISSN: 0012-6667 [Print] New Zealand
• PMID: 10493276 (Publication Type: Journal Article, Review)

Chemical References

• Indoles
• Placebos
• Serotonin Receptor Agonists
• tegaserod

Topics

• Clinical Trials as Topic
• Colonic Diseases, Functional (drug therapy)
• Electroencephalography (drug effects)
• Humans
• In Vitro Techniques
• Indoles (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Placebos
• Serotonin Receptor Agonists (adverse effects, pharmacokinetics, pharmacology, therapeutic use)